Arch Biopartners (ARCH) AI Stock Analysis

• Market Cap: C$38.15M
• Dividend Yield: N/A
• Average Volume (3M): 43.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: N/A
• EPS Growth: 10.49%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 66,933,290
• 10 Day Avg. Volume: 31,059
• 30 Day Avg. Volume: 43,967
• PEG Ratio: 0.88
• Price to Book (P/B): -21.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -53.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.16
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.54 ▼(-60.29% Downside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is primarily held down by weak financial performance (no TTM revenue, persistent losses, negative equity, and ongoing cash burn). Technical indicators also point to a bearish trend with weak momentum. Valuation does not provide support due to negative earnings and no dividend yield data.

Positive Factors

Differentiated therapeutic platform

A focused platform (DPEP-1 inhibitor plus an extracellular-histone mAb) provides clear scientific differentiation across acute/inflammatory indications. This platform focus can concentrate R&D, create multiple asset-level value paths, and improve partner interest over months to years.

Clinical-stage asset base

Being clinical-stage means programs have progressed beyond preclinical work, reducing early-stage technical risk. Near-term clinical readouts or regulatory interactions can materially de-risk programs and materially improve partnerability and licensing leverage over a 2–6 month horizon.

Partnering/licensing monetization pathway

A business model built on out-licensing and milestones is capital efficient for a clinical-stage biotech: it enables program advancement with limited internal commercialization spend and offers potential non-dilutive or milestone-driven funding that can sustainably finance development if partnerships materialize.

Negative Factors

Zero reported revenue and ongoing losses

No recurring revenue and persistent negative operating/free cash flow indicate structural funding dependence. Continued losses require regular external capital or partnering, which can dilute existing holders or constrain program timelines if financing windows tighten over the next several quarters.

Negative equity and thin asset base

Negative equity, meaningful debt and negligible tangible assets limit financial flexibility and bargaining power with partners or lenders. This fragile capital structure raises the risk of dilutive financings or constrained R&D investment, impacting program execution durability.

Operational capacity constraints

Reported zero employees implies heavy reliance on contractors, contractors or external partners to run development. That structure can increase program execution risk, slow timelines, and raise per-program costs, reducing operational resilience across the medium term.

Arch Biopartners Business Overview & Revenue Model

Company Description

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.

How the Company Makes Money

Arch Biopartners does not appear to be a commercial-stage company and, based on publicly available high-level disclosures, it has not indicated recurring product sales as a primary source of revenue. Its typical expected ways of generating revenue are through (i) out-licensing or partnering its drug candidates/platform (e.g., granting pharmaceutical partners rights to develop and commercialize in certain territories or indications) in exchange for upfront payments, development/regulatory milestone payments, and downstream royalties on net sales if a partnered product reaches the market; and/or (ii) raising capital via equity financings to fund R&D until a licensing deal or commercialization. Specific, quantifiable revenue streams (e.g., current licensing income amounts, named commercial partnerships with payment terms, or product sales) are not available from the information provided here; therefore, any current material revenue source beyond potential financing/partnering economics is null.

Arch Biopartners Financial Statement Overview

Summary

Financial strength is very weak: TTM revenue is $0, net losses persist (TTM about -$2.7M), operating/free cash flow are negative (TTM about -$1.5M), and stockholders’ equity is negative (TTM about -$3.6M). The thin asset base and ongoing burn imply continued reliance on external funding.

Income Statement

Profitability is weak and inconsistent. TTM (Trailing-Twelve-Months) revenue is $0 with a net loss of about $2.7M, following multiple years of losses (annual net income roughly -$1.2M to -$3.9M). Revenue has been volatile (strong growth in 2023 vs. 2022, modest growth in 2024), and margins have generally been deeply negative, indicating the business is still heavily in investment/burn mode with limited near-term earnings visibility.

Balance Sheet

Balance sheet risk is elevated. Stockholders’ equity is negative in every period shown (TTM about -$3.6M), which limits financial flexibility and increases reliance on external funding. Debt remains material (TTM about $2.6M; higher in prior years), and total assets are very small in TTM ($25K), highlighting a thin capital base relative to ongoing losses.

Cash Flow

Cash generation is weak, with persistent cash burn. TTM (Trailing-Twelve-Months) operating cash flow is about -$1.5M and free cash flow is also about -$1.5M, and free cash flow growth is negative in TTM. While annual cash burn has fluctuated (notably much lower in 2023 vs. 2021/2024), the overall pattern remains consistently negative, implying continued funding needs absent a step-change in revenue or cost structure.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	2.12M	1.98M	964.68K	3.89M
Gross Profit	0.00	-1.66M	-129.00K	-503.00K	-150.00K
EBITDA	-1.29M	-3.53M	-336.00K	-101.00K	-77.02K
Net Income	-1.55M	-3.92M	-3.33M	-1.41M	-1.17M
Balance Sheet
Total Assets	104.53K	935.62K	1.17M	621.64K	2.67M
Cash, Cash Equivalents and Short-Term Investments	2.10K	2.97K	831.27K	506.35K	448.24K
Total Debt	2.84M	2.77M	5.02M	4.41M	5.16M
Total Liabilities	3.99M	5.28M	6.68M	5.09M	6.55M
Stockholders Equity	-3.88M	-4.35M	-5.51M	-4.47M	-3.88M
Cash Flow
Free Cash Flow	-1.58M	-2.33M	-234.08K	-1.08M	-2.98M
Operating Cash Flow	-1.58M	-2.33M	-234.07K	-1.08M	-2.98M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	1.58M	1.50M	559.00K	-421.37K	2.78M

Arch Biopartners Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Negative. The current price of 1.37 is above the 20-day moving average (MA) of 0.76, above the 50-day MA of 0.97, and above the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 19.19 is Positive, neither overbought nor oversold. The STOCH value of 8.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ARCH.

Arch Biopartners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MSCL	46 Neutral	$156.44M	-5.03	-89.10%	―	―	27.53%
BCT	46 Neutral	C$41.33M	-0.41	-205.87%	―	―	62.01%
MDNA	42 Neutral	C$48.11M	-4.40	-103.51%	―	―	54.74%
ARCH	41 Neutral	C$38.15M	-12.93	72.34%	―	―	10.49%